Biomarker: lymphocyte activation gene-3

Histology type: endometrial cancer

Country: China

Region: Beijing

Followed up time :

Conclusion: This study suggests that immunotherapy targeting LAG-3 may play a role in EC patients with POLEmut or MMRd molecular markers. Positive LAG-3 expression in TCs may be a predictor of improved RFS.

Sample type : tissues

Sample method: immunohistochemistry

Expression pattern : upregulated

Funtion Uniprot: Lymphocyte activation gene 3 protein: Inhibitory receptor on antigen activated T-cells (PubMed:7805750, PubMed:8647185, PubMed:20421648). Delivers inhibitory signals upon binding to ligands, such as FGL1 (By similarity). FGL1 constitutes a major ligand of LAG3 and is responsible for LAG3 T-cell inhibitory function (By similarity). Following TCR engagement, LAG3 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation (By similarity). May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1, possibly by acting as a coreceptor for PDCD1/PD-1 (By similarity). Negatively regulates the proliferation, activation, effector function and homeostasis of both CD8+ and CD4+ T-cells (PubMed:7805750, PubMed:8647185, PubMed:20421648). Also mediates immune tolerance: constitutively expressed on a subset of regulatory T-cells (Tregs) and contributes to their suppressive function (By similarity). Also acts as a negative regulator of plasmacytoid dendritic cell (pDCs) activation (By similarity). Binds MHC class II (MHC-II); the precise role of MHC-II-binding is however unclear (PubMed:8647185)

UniProt ID: P18627

UniProt Link: https://www.uniprot.org/uniprotkb/P18627

Biological function from UniProt: #Adaptive immunity #Immunity

Molecular function from UniProt:

Tissue specificity from UniProt: Primarily expressed in activated T-cells and a subset of natural killer (NK) cells.

Subcellular UniProt: #Cell membrane #Membrane #Secreted

Recommended name: Lymphocyte activation gene 3 protein

Gene name from HGNC: LAG3

HPA class: CD markers FDA approved drug targets

AlphaFold DB: P18627

AlphaFold Link: https://alphafold.ebi.ac.uk/entry/P18627

Induction: Expression is induced by interleukin-2 (IL2), interleukin-7 (IL7) and interleukin-12 (IL12A and IL12B) on activated T-cells.

HPA link: https://www.proteinatlas.org/ENSG00000089692-LAG3

Tissue specificity RNA from HPA: Tissue enhanced (choroid plexus, lymphoid tissue, ovary)

Tissue expression from HPA: Lymphoid tissue - Immune response (mainly)

Single cell type specificity Cell type enhanced (Peritubular cells, T-cells, Leydig cells, Ovarian stromal cells)

Immune cell specificity: Immune cell enhanced (gdT-cell, memory CD8 T-cell, MAIT T-cell)

Cancer prognostic summary HPA Prognostic marker in renal cancer (unfavorable) and cervical cancer (favorable)

Pathology link: https://www.proteinatlas.org/ENSG00000089692-LAG3/pathology

Pathology endo: https://www.proteinatlas.org/ENSG00000089692-LAG3/pathology/endometrial+cancer

OMIM: 153337

OMIM link2: https://www.omim.org/entry/153337

HGNC ID: HGNC:6476

HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6476